Monday, 21 Aug 2017

You are here

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

  1. ARTIS RA registry shows those initiating a TNFi within 5 yrs of onset double their odds of returning to work in 3 yrs https://t.co/WytSlSYRj1
  2. ARTIS & DANBIO registries: 8703 SpA (AS, PsA) patients treated with TNFI: they do NOT have an increase risk of cancer overall; nor the 6 most common types CA http://buff.ly/2icvD9O
  3. Hepatosplenic T cell lymphoma: review shows this to be a very rare event with TNFi; but is more common in IBD pts (younger), receiving thiopurines. http://buff.ly/2jn7Bqm
  4. Biosimilar Inflectra priced at only a 15% discount; CMS issues payment and claims processing information https://t.co/lCwn198PAN
  5. There is no interaction between low dose weekly MTX and NSAIDs, PCNs or PPIs. https://t.co/h4JeLoSbEg
  6. FDA reviewing a new drug application (NDA) for the new combo drug: allopurinol + lesinurad (Ironwood Pharm) to Rx hyperuricemia and uncontrolled gout https://t.co/e95R8TlXuv
  7. Meta-analysis of 1069 knee OA patients- intraarticular Platelet Rich Plasma (vs HA, NS) shows significantly better WOMAC pain/function scores. @12mo https://t.co/LBJt2SbZXO,
  8. Chronic PPI use associated with 74% more C difficile infections & 2.5-fold increased risk of recurrent C difficile with chronic PPI https://t.co/W1mLbPEPYP
  9. 13% of US African Americans have diabetes; but AA are seldom included in diabetes clinical trials. Whatsupwiththat? https://t.co/GYgXnAcyzb
  10. Total knee vs hemiarthroplasty show equal outcomes;more complications with bilateral total knee replacements (pt selection is critical to the success of hemiarthroplasty) https://t.co/D8OXH8VnTA
  11. 94 pts with MTX pancytopenia in elderly; 24% mortality; risk factors include age>65, sepsis + hypoalbuminemia https://t.co/7p99v9bt3g
  12. Multiple Comorbidity Risks with Giant Cell Arteritis
  13. Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death? 
  14. The IL-6 Wars 
  15. DMARDs Under Study for Secondary Prevention of Cardiovascular Events

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on lupus survival, pediatric lupus guidelines from SHARE, room temperature storage of etanercept, over or under-testing by rheumatologists and failure of pain meds to treat pain.

The RheumNow Week in Review – 11 August 2017

The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.  This week's news highlights include new data on the incidence of arthritis, lag times in patient referral, criteria for referral and why/how weather change affects arthritis pain.

Criteria for Early Referrals from Primary Care

Early diagnosis and early intervention has been the mantra of all who manage musculoskeletal (MSK) diseases for decades. While the rules for referral may be clear to some, the lack of uniformity and promotion amongst primary care providers is less certain.

MSK Ultrasound Now Standard for Rheumatology Training

In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.